Kiadis announces first patient enrolled in clinical study conducted
at The Ohio State University in R/R AML with off-the-shelf K-NK
cells from universal donors as part of its K-NK003 program
Amsterdam, The Netherlands, June 25, 2020 –
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam
and Brussels: KDS), a clinical stage biopharmaceutical
company, and The Ohio State University Comprehensive Cancer Center
– Arthur G. James Cancer Hospital (OSUCCC-James), today announced
that the first patient has been enrolled and treated in a phase I,
first-in-human clinical trial in patients with relapsed/refractory
acute myeloid leukemia (“R/R AML”) with off-the-shelf Natural
Killer (“NK”) cells manufactured at the Cell Therapy laboratory at
the OSUCCC-James using Kiadis’ FC21 and proprietary universal donor
platforms. The trial is being conducted at the OSUCCC-James and is
expected to provide valuable data to support Kiadis’ K-NK003
development program.
The phase I study, NCT04220684, will evaluate
the NK cell product in up to 56 patients, ages 18 – 80 who have
primary refractory AML, relapsed AML, or myelodysplastic syndromes
(“MDS”). The goal of this study is to establish safety of the NK
cell therapy for the induction of remission in patients with R/R
AML or MDS and to determine the optimal dosing and overall response
rate. Patients enrolled in the study will receive six doses of NK
cells of 1 x 107 cells/kg to 1 x 108 cells/kg after receiving
reinduction chemotherapy. The trial is expected to provide further
clinical proof-of-concept of Kiadis’ K-NK003 product. Kiadis is
supporting the Investigator-sponsored study through a collaborative
research agreement with OSUCCC-James.
Sumithira Vasu, MBBS, the principal investigator
of the clinical trial, hematologist and scientist, Medical Director
of the Cell Therapy Lab at OSUCCC-James, and associate professor at
the Ohio State College of Medicine says, “This off-the-shelf
universal donor NK cell therapy is an exciting new experimental
treatment option for patients with R/R AML and MDS that allows us
to infuse large numbers of hyperfunctional NK cells immediately
when needed. Treating our first patient with this therapy is an
important step in this ongoing clinical research.”
Andrew Sandler, MD, chief medical officer of
Kiadis commented, “This trial uses a novel off-the-shelf, readily
available NK cell product to treat a very sick and
difficult-to-treat group of patients. We are very enthusiastic with
the initiation of this trial and to be one step closer to bringing
K-NK-cell therapies to a broad patient population across a
potentially wide range of cancers.”
Kiadis contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring LifeSciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Kiadis Pharma N.V. (‘Kiadis’ of de
‘Onderneming’) (Euronext Amsterdam en Brussel: KDS), een
biofarmaceutisch bedrijf gericht op onderzoek in de klinische fase,
en de Comprehensive Cancer Center – Arthur G. James Cancer Hospital
van de Ohio State University (‘OSUCCC-James’), kondigen aan dat de
eerste patiënt is behandeld in een fase-I klinische studie voor
behandeling van patiënten met recidiverende of refractaire acute
myeloïde leukemie (R/R AML). De studie wordt uitgevoerd door de
OSUCCC-James met NK-cellen geproduceerd in het Cell Therapy
laboratorium aan de OSUCCC-James op basis van de Kiadis FC21- en
universele-donorplatforms. De studie zal naar verwachting
waardevolle gegevens leveren voor het K-NK003 product van
Kiadis.
In de fase-I studie (NCT04220684) wordt het
NK-celproduct geëvalueerd bij maximaal 56 patiënten van 18-80 jaar
met primaire refractaire AML, recidiverende AML of
myelodysplastische syndromen (MDS). Het doel van de studie is om
veiligheid, inductie van remissie, optimale dosering en
responspercentage met NK celtherapie vast te stellen bij deze
patienten. Deelnemende patiënten krijgen zes doseringen NK-cellen
van 1 x 107 cellen/kg tot 1 x 108 cellen/kg. Kiadis ondersteunt de
studie door middel van een onderzoeksovereenkomst met Ohio
State University.
Dit persbericht vormt een vertaling van het
gepubliceerde Engelstalige persbericht. Bij eventuele verschillen
is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis’ K-NK-cell
Therapies Kiadis’ NK-cell programs consist of
off-the-shelf and haplo donor cell therapy products for the
treatment of liquid and solid tumors as adjunctive and stand-alone
therapies.
The Company’s NK-cell PM21 particle technology
enables improved ex vivo expansion and activation of anti-cancer
cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis’
proprietary off-the-shelf NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis is clinically developing K-NK003 for the
treatment of relapse/refractory acute myeloid leukemia. The Company
is also developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About Relapsed/Refractory Acute Myeloid
Leukemia (R/R AML) Acute myelogenous leukemia (AML) is the
most common type of acute leukemia in adults and has the lowest
survival rate of all leukemias. AML relapse affects nearly half of
all leukemia patients who achieved remission after initial
treatment and can continue to occur several months to several years
after treatment with the majority of relapses occurring within two
to three years of the initial treatment. Patients with relapsed or
refractory leukemia have limited treatment options and poor
survival rates.
The goal of treatment for acute myeloid leukemia
(AML) is to put the leukemia into complete remission and to keep it
that way. Unlike conventional chemotherapy options, which primarily
target dividing cells, immunotherapeutic therapies aim at directing
an immune response against tumor cells. Natural Killer (NK) cells
are effector lymphocytes of the innate immune system capable of
exerting anti-AML activity. The K-NK cell platform is a cell-based
immunotherapy to treat patients with advanced blood cancer.
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis is reimagining medicine by leveraging the natural strengths
of humanity and our collective immune system to source the best
cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person’s officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.